Tekton Research Adds Fourth Clinical Site in 2025 with Richmond Pediatric Associates Partnership
Key Insights
Tekton Research (search) has partnered with Richmond Pediatric Associates (search) as its fourth new clinical research site in 2025, expanding pediatric research capabilities in diabetes (search), obesity (search), ADHD (search), and mood disorders.
The Virginia-based multi-physician clinic, led by Dr. David Gosselin, represents Tekton's second location in the Richmond region alongside Virginia Endocrinology (search), enabling longitudinal studies across adult and pediatric populations.
This strategic expansion brings Tekton's nationwide network to more than 25 active research sites, focusing on therapeutic areas with high unmet medical need while bringing research closer to real-world communities.
Tekton Research (search) has announced its fourth new clinical research site partnership of 2025, adding Richmond Pediatric Associates (search) to its expanding nationwide network. The Virginia-based multi-physician clinic specializes in comprehensive pediatric and adolescent care, bringing critical research capabilities in diabetes (search), obesity (search), ADHD (search), and mood disorders including anxiety (search) and major depressive disorder (search).
Led by Dr. David Gosselin, Richmond Pediatric Associates (search) represents Tekton's second location in the Richmond region, following the recent addition of Virginia Endocrinology (search). The strategic positioning of both practices creates unique opportunities for longitudinal studies and family-based recruitment models that span both adult and pediatric patient populations.
Strategic Geographic Expansion
The partnership aligns with Tekton's broader demographic and geographic expansion strategy for 2025, which prioritizes enhanced recruitment potential and sustainable site operations while bringing research opportunities closer to real-world communities.
"When evaluating new partnerships, we consider more than therapeutic alignment—we assess regional population density, clinic relationships, and how our footprint can support stronger recruitment and continuity of care," said Jeffrey Zucker, Chief Expansion Officer at Tekton. "Richmond Pediatrics is a prime example of a site that fits this strategy while opening doors to a critical pediatric demographic."
Dr. Gosselin emphasized the clinical significance of the partnership for families managing chronic pediatric conditions. "We are thrilled to bring clinical research into our practice and begin this journey with Tekton Research (search)," he said. "We see firsthand the challenges families face in managing chronic pediatric conditions, and participating in research gives us the chance to contribute to the development of new therapies that can change lives. This partnership allows us to offer our patients even more ways to receive cutting-edge care while contributing to the future of medicine."
2025 Network Growth
Richmond Pediatric Associates (search) joins three other new sites that Tekton has added to its network in 2025. In March, the company welcomed Dr. Ernest Graypel of Community and Long-Term Care Psychiatry (search) in Saint Louis, Missouri, bringing expertise in schizophrenia (search), dementia (search), and Alzheimer's disease (search) across hard-to-reach long-term care populations.
April saw the addition of Empower Psychiatry & Sleep (search) in Georgia, led by Dr. Ravi Singareddy, expanding capabilities in mental health and sleep medicine including insomnia (search), depression (search), PTSD (search), and anxiety (search) disorders. Virginia Endocrinology (search) joined the network in May, enhancing research capabilities in endocrine disorders including type 2 diabetes (search), obesity (search), and osteoporosis (search).
Network Scale and Focus
With the Richmond Pediatric Associates (search) partnership, Tekton now operates more than 25 active research sites nationwide, with continued expansion planned throughout 2025 and beyond. Founded in 2006, the company conducts Phase 1-4 trials across CNS, cardiometabolic, general medicine, and infectious disease therapeutic areas.
The network is led by seasoned professionals and nationally recognized key opinion leaders, delivering scientific rigor and operational excellence for trials of varying sizes. Tekton partners with sponsors, contract research organizations, and biopharmaceutical companies to accelerate new therapy development while maintaining a commitment to patient-centered care.